ARCHIVES

As For-Profits Provide Phase I Studies, NCI Seeks to Look Deeper and Learn More

This article is from The Cancer Letter archive.

Vol. 38 No. 14 | April 6, 2012

Download PDF Visit The Full Archive

Related Articles

Number of Clinical R01 Applications Doubles; Funding Rate Below 20%; NCI Execs Not Satisfied

July 17, 1992

Seven New Initiatives For NIH Common Fund

February 26, 2010

FDA Advisors Unanimously Turn Down GPC Biotech’s Orplatna for Prostate Cancer.

July 27, 2007

Garfinkel to Retire From ACS; Health to Succeed Him

July 20, 1990

Professional Fundraiser Poses Eight Questions For SU2C 3.

September 19, 2008

Diet/Nutrition Advisory Group Blast Fund Limit, Incurs Schmidt Wrath

February 4, 1977